--- title: "Tempest Therapeutics (TPST) news: going concern and offering" url: "https://aibio.space/companies/tempest-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TPST going concern, offering and Nasdaq notice news: Tempest Therapeutics gets Nasdaq notice on stockholders' equity, flags board independence gap." --- TPST Tempest Therapeutics, Inc. NASDAQ · United States # Tempest Therapeutics (TPST) news TPST going concern, offering and Nasdaq notice news Listings · 2026-05-22 ## [Tempest Therapeutics gets Nasdaq notice on stockholders' equity, flags board independence gap](https://aibio.space/news/tempest-therapeutics-gets-nasdaq-notice-stockholders-equity-flags/) Tempest reported $822,000 of stockholders' equity against Nasdaq's $2,500,000 minimum, and two director resignations leave it short of several board rules. Its 10-K already carried a going-concern warning. ## Latest Tempest Therapeutics news 1. 2025-06-12 Financings [Tempest Therapeutics prices $6.25 registered direct offering, expects $4.1 million net](https://aibio.space/news/tempest-therapeutics-prices-6-25-registered-direct-offering-expects-4/) Tempest sold 405,000 shares and prefunded warrants for 334,000 shares to one institutional investor at $6.25 each, for about $4.1 million net. The company's cash estimate runs only into the second quarter of 2026, and it is exploring strategic alternatives. 2. 2025-04-28 Listings [Tempest Therapeutics regains compliance with Nasdaq $1.00 bid price rule](https://aibio.space/news/tempest-therapeutics-regains-compliance-nasdaq-1-00-bid-price-rule/) Nasdaq sent the company a formal notice of compliance on April 24, 2025. The 8-K does not say how the price was restored, and the lead drug's Phase 3 timeline is subject to funding. 3. 2025-04-18 Distress [Tempest Therapeutics cuts 21 of 26 employees as it explores strategic alternatives](https://aibio.space/news/tempest-therapeutics-cuts-21-26-employees-explores-strategic/) Tempest Therapeutics will cut 21 of its 26 full-time employees as it explores strategic alternatives, with cuts effective April 30, 2025. It expects about $1.5 million in cash costs, mostly severance, and its 2024 10-K said cash of $30.3 million would last at least 12 months. ## Tempest Therapeutics at a glance - **Ticker**: TPST - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $779,000 ### Related companies - [Dare Bioscience](https://aibio.space/companies/dare-bioscience/) NASDAQ: DARE - [Niki BioSolutions](https://aibio.space/companies/niki-biosolutions/) NASDAQ: NIKI - [Royalty Pharma](https://aibio.space/companies/royalty-pharma/) NASDAQ: RPRX - [Skye Bioscience](https://aibio.space/companies/skye-bioscience/) NASDAQ: SKYE - [Biogen](https://aibio.space/companies/biogen/) NASDAQ: BIIB - [vTv Therapeutics](https://aibio.space/companies/vtv-therapeutics/) NASDAQ: VTVT - [Annexon](https://aibio.space/companies/annexon/) NASDAQ: ANNX - [AEON Biopharma](https://aibio.space/companies/aeon-biopharma/) AMEX: AEON ### Also on NASDAQ - [Insmed](https://aibio.space/companies/insmed/) INSM - [Instil Bio](https://aibio.space/companies/instil-bio/) TIL - [Iambic Therapeutics](https://aibio.space/companies/iambic-therapeutics/) IAM - [Beam Therapeutics](https://aibio.space/companies/beam-therapeutics/) BEAM - [Mineralys Therapeutics](https://aibio.space/companies/mineralys-therapeutics/) MLYS - [Puma Biotechnology](https://aibio.space/companies/puma-biotechnology/) PBYI ## Tempest Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$26.3 million](https://www.sec.gov/Archives/edgar/data/1544227/000119312526130490/) | [-$41.8 million](https://www.sec.gov/Archives/edgar/data/1544227/000119312526130490/) | | Cash from operations | [-$26.8 million](https://www.sec.gov/Archives/edgar/data/1544227/000119312526130490/) | [-$33.0 million](https://www.sec.gov/Archives/edgar/data/1544227/000119312526130490/) | | Cash and equivalents | [$7.7 million](https://www.sec.gov/Archives/edgar/data/1544227/000119312526349381/) | [$30.3 million](https://www.sec.gov/Archives/edgar/data/1544227/000119312526130490/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $779,000. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Tempest Therapeutics Has Tempest Therapeutics issued a going-concern warning? Our latest story on this, dated May 22, 2026: "Tempest Therapeutics gets Nasdaq notice on stockholders' equity, flags board independence gap". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tempest-therapeutics-gets-nasdaq-notice-stockholders-equity-flags/). Has Tempest Therapeutics raised money recently? Our latest story on this, dated Jun 12, 2025: "Tempest Therapeutics prices $6.25 registered direct offering, expects $4.1 million net". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tempest-therapeutics-prices-6-25-registered-direct-offering-expects-4/). Has Tempest Therapeutics received a Nasdaq deficiency notice? Our latest story on this, dated May 22, 2026: "Tempest Therapeutics gets Nasdaq notice on stockholders' equity, flags board independence gap". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tempest-therapeutics-gets-nasdaq-notice-stockholders-equity-flags/). What is the ticker symbol of Tempest Therapeutics? Tempest Therapeutics, Inc. trades under the ticker TPST on NASDAQ. Where is Tempest Therapeutics listed? Tempest Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Tempest Therapeutics? The SEC Central Index Key (CIK) for Tempest Therapeutics, Inc. is 1544227. Its filings are on SEC EDGAR. How many shares does Tempest Therapeutics have outstanding? 14,806,997 shares as of 2026-05-08, per the cover page of its 10-Q filed 2026-05-14. Which country or territory is Tempest Therapeutics listed under? Our directory records Tempest Therapeutics, Inc. under United States. What does Tempest Therapeutics do? Our directory classifies Tempest Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Tempest Therapeutics? The ISIN recorded for Tempest Therapeutics, Inc. is US87978U2078. Does aibio.space cover Tempest Therapeutics? aibio.space lists Tempest Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Tempest Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Tempest Therapeutics profitable? Tempest Therapeutics, Inc. reported a net loss of $26.3 million for the fiscal year ended Dec 31, 2025, and used $26.8 million of cash in operations, per its annual report to the SEC. How much cash does Tempest Therapeutics have? $779,000 in cash at Jun 30, 2026, per its 10-Q. What is the latest Tempest Therapeutics (TPST) stock news? Our latest story on Tempest Therapeutics, dated May 22, 2026: "Tempest Therapeutics gets Nasdaq notice on stockholders' equity, flags board independence gap". Tempest reported $822,000 of stockholders' equity against Nasdaq's $2,500,000 minimum, and two director resignations leave it short of several board rules. Its 10-K already carried a going-concern warning. [Source](https://aibio.space/news/tempest-therapeutics-gets-nasdaq-notice-stockholders-equity-flags/). ## Investor discussion: Tempest Therapeutics Members talk about Tempest Therapeutics (TPST). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Tempest Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-09-15 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312526391903/d108044d8k.htm) 2. 2026-08-13 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312526349334/d290418d8k.htm) 3. 2026-05-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312526237207/d131489d8k.htm) 4. 2026-02-06 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,3.02,5.01,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312526041190/d159400d8k.htm) 5. 2026-01-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312526008938/d30095d8k.htm) 6. 2025-11-19 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312525287163/d97617d8k.htm) 7. 2025-06-12 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312525139623/d14857d424b5.htm) 8. 2025-05-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1544227/000095017025070441/tpst-20250331.htm) 9. 2025-04-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312525098817/d935409d8k.htm) 10. 2025-04-18 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312525085773/d792758d8k.htm) 11. 2025-04-09 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312525076938/d906762dex991.htm) 12. 2025-04-07 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312525073987/d905141d8k.htm) 13. 2025-02-06 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312525021851/d485087d424b5.htm) 14. 2024-12-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312524287170/d848354d8k.htm) 15. 2024-12-06 Listings Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1544227/000119312524272464/d899818d8k.htm) 16. 2024-11-12 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1544227/000114036124046210/ny20036455x2_def14a.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TPST on TradingView](https://www.tradingview.com/symbols/NASDAQ-TPST/). ## SEC filings and registration - **SEC name**: Tempest Therapeutics, Inc. - **CIK**: 1544227 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TPST (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 2000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005 - **Phone**: 415-798-8589 - **Shares outstanding**: 14,806,997 as of 2026-05-08 (10-Q filed 2026-05-14) - **Former names**: Millendo Therapeutics, Inc.; OvaScience, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1544227/000121390026111026/ea0309080-8k_tempest.htm) filed 2026-10-20 - [8-K](https://www.sec.gov/Archives/edgar/data/1544227/000121390026110669/ea0309028-8k_tempest.htm) filed 2026-10-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1544227/000121390026104034/ea0306741-8k_tempest.htm) filed 2026-09-28 - [S-3](https://www.sec.gov/Archives/edgar/data/1544227/000121390026103526/ea0306626-s3_tempest.htm) filed 2026-09-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1544227/000119312526394492/d185404d8k.htm) filed 2026-09-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1544227/000119312526393151/d151966d8k.htm) filed 2026-09-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1544227/000119312526391903/d108044d8k.htm) filed 2026-09-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1544227/000119312526363695/d152818d8k.htm) filed 2026-08-24 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001544227), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Tempest Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TPST, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Tempest Therapeutics, Inc. - **Ticker**: TPST - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US87978U2078 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TPST/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/tempest-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Tempest Therapeutics (TPST) news: going concern and offering", 2026-10-31, https://aibio.space/companies/tempest-therapeutics/